Trials / Completed
CompletedNCT01390519
A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor
Observational Study Evaluating Efficacy, Tolerability and Treatment Algorithm of Advanced Renal Cell Cancer Patients Under Afinitor Treatment
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Norwegian prospective registration, observational study of patients with advanced renal cell cancer on Afinitor treatment after failure of one Tyrosine Kinase Inhibitor (TKI) ( e.g. sunitinib or sorafenib). The goal is to document the treatment algorithm of these patients in Norway and the efficacy and tolerability of Afinitor® in a pure 2.line setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | everolimis |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2011-07-11
- Last updated
- 2016-01-13
Locations
3 sites across 1 country: Norway
Source: ClinicalTrials.gov record NCT01390519. Inclusion in this directory is not an endorsement.